Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19077428 | TRADITIONAL CHINESE HERBAL PLANT COMPOSITION FOR IMPROVING SYMPTOMS OF LIVER CANCER PATIENTS AND COMPATIBILITY METHOD THEREOF | March 2025 | June 2025 | Allow | 3 | 0 | 0 | No | No |
| 19059879 | SILVER COMPOUND PREPARATION AND APPLICATION OF SILVER COMPOUND PREPARATION IN TREATMENT OF CUTANEOUS FUNGAL INFECTIONS AND ECZEMA | February 2025 | September 2025 | Allow | 7 | 1 | 0 | No | No |
| 18639758 | KAVA COMPOSITIONS AND METHODS OF USE | April 2024 | May 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18621669 | Local Drug Delivery Devices and Methods for Treating Cancer | March 2024 | December 2025 | Allow | 20 | 1 | 0 | No | No |
| 18511152 | METHOD OF MAKING SILVER NANOPARTICLES CAPPED WITH CARALLUMA SINAICA EXTRACT AND TREATMENT METHOD USING THE SAME | November 2023 | December 2024 | Allow | 13 | 2 | 0 | No | No |
| 18389181 | ANTIBIOTIC WITH SPIRULINA PLATENSIS AND PLANT EXTRACTS | November 2023 | November 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18213022 | KAVA COMPOSITIONS AND METHODS OF USE | June 2023 | March 2025 | Allow | 20 | 3 | 1 | Yes | Yes |
| 18338002 | METHODS OF DEPOSITING SILVER NANOSTRUCTURES ON TO IMPLANT SURFACES | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18032957 | COMPOSITION FOR PREVENTING, IMPROVING, OR ALLEVIATING MENSTRUAL SYMPTOMS | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18133240 | CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE | April 2023 | January 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18129182 | METHODS OF DIAGNOSING AND TREATING DRY EYE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE | March 2023 | September 2024 | Allow | 18 | 1 | 0 | No | No |
| 18107544 | METHOD OF REDUCING MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE BY ADMINISTERING PURPLE-TEA EXTRACT | February 2023 | September 2024 | Allow | 19 | 1 | 0 | No | No |
| 18019671 | PHYTOTHERAPEUTIC COMPOSITION | February 2023 | March 2026 | Abandon | 37 | 1 | 1 | No | No |
| 18102541 | AGGREGATING MICROPARTICLES FOR MEDICAL THERAPY | January 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18095493 | METHOD OF USING EXTRACT OF DENDROBII CAULIS AND METHOD OF PROTECTING EYE | January 2023 | July 2025 | Allow | 30 | 5 | 0 | Yes | No |
| 18146973 | MICROARRAY FOR DELIVERY OF THERAPEUTIC AGENT AND METHODS OF USE | December 2022 | January 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18086817 | COMPOSITION OF MATTER TO REDUCE BREAST LACTATION AND ENGORGEMENT | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18081226 | STEAMED GLYCYRRHIZA SP. EXTRACT WITH INCREASED GLYCYRRHETINIC ACID CONTENTS AND PREPARATION METHOD THEREOF | December 2022 | October 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 18056988 | HERBAL COMPOSITION, PREPARATION METHOD THEREOF AND METHOD FOR PREVENTING OR TREATING RESPIRATORY DISORDER BY ADMINISTERING THE SAME | November 2022 | March 2026 | Allow | 50 | 1 | 1 | No | No |
| 17985097 | METHODS AND FORMULATIONS FOR TREATING AND PREVENTING LONG HAUL CORONAVIRUS (LONG COVID) SYMPTOMS AND SEQUELAE | November 2022 | March 2026 | Abandon | 40 | 1 | 1 | No | No |
| 18053224 | DISINFECTANTS WITH IODINE AND COPPER COMPLEXES | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 17959449 | METHOD FOR TREATING CORONAVIRUS INFECTIOUS DISEASE AND COMPLICATED SEVERE COMA, ULTRA-LOW BLOOD OXYGEN, MORIBUND DISEASE THEREOF | October 2022 | March 2026 | Allow | 41 | 2 | 1 | No | No |
| 17957288 | USE OF HUANGQI EXTRACT FOR SUPPRESSING SARS-COV-2 ENTRY AND TREATING COVID-19 RELATED CYTOKINE STORM | September 2022 | March 2026 | Abandon | 41 | 2 | 0 | No | No |
| 17947793 | ANTIBIOTIC WITH SPIRULINA PLATENSIS AND PLANT EXTRACTS | September 2022 | August 2023 | Abandon | 11 | 3 | 1 | No | No |
| 17758668 | PHAGOSTIMULANT FORMULATION FOR CONTROL OF PEST | July 2022 | September 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17810363 | POLYGONI MILLETII RHIZOME COMPOSITIONS AND METHODS OF PREPARING THE SAME | July 2022 | December 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17850968 | LIGHT ACTIVATED GASOTRANSMITTER GENERATING COMPOSITIONS | June 2022 | July 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17841364 | MEDICAL TABLET, AND MANUFACTURING METHOD AND MANUFACTURING APPARATUS FOR MEDICAL TABLET | June 2022 | November 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17834014 | SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS | June 2022 | December 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17828557 | Method of Providing Oral Care Benefits | May 2022 | March 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17747347 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF ATOPIC DERMATITIS DISEASE | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17764985 | GINGER DERIVED EXTRACELLULAR VESICLES AND USE THEREOF | May 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17755824 | COMPOSITION FOR THE MAKING OF AN EMULSIFIABLE TRIPHASIC FORMULATION, AND KIT FOR THE USE OF SUCH COMPOSITION | May 2022 | September 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17755601 | 1-(((2S,3S,4S)-3-ETHYL-4-FLUORO-5-OXOPYRROLIDIN-2-YL)METHOXY)-7-METHOXYISOQUINOLINE-6-CARBOXAMIDE COMBINATIONS AND ORAL DOSAGE FORMS | May 2022 | March 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17728041 | MODIFIED HERBAL COMPOSITIONS FOR NEUROMODULATION | April 2022 | November 2024 | Allow | 31 | 3 | 1 | Yes | No |
| 17771671 | BLEACHING POWDER COMPOSITION | April 2022 | December 2025 | Allow | 44 | 3 | 0 | No | No |
| 17721445 | COMPOSITIONS OF FLUOROCARBON NANOEMULSION, AND METHODS OF PREPARATION AND USE THEREOF | April 2022 | March 2025 | Abandon | 35 | 4 | 0 | No | No |
| 17720720 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRE-DIABETES, DIABETES AND METABOLIC SYNDROME | April 2022 | May 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17640534 | TREATMENT AND PREVENTION OF PULMONARY INJURY | March 2022 | October 2025 | Allow | 44 | 2 | 0 | No | No |
| 17640147 | Electrically Conductive Hydrogels Usable As Lead Extensions, Apparatus For Delivery Of A Hydrogel Into The Vasculature, and Methods Of Treating Ventricular Arrhythmia With Electrically Conductive Hydrogels Injected In The Venous System | March 2022 | June 2025 | Allow | 39 | 1 | 1 | No | No |
| 17638633 | COMPOSITION CONTAINING EXTRACT OF LILIUM HANSONII LEICHTLIN EX BAKER | February 2022 | October 2025 | Allow | 44 | 3 | 0 | Yes | No |
| 17674642 | COMPOSITIONS AND METHODS FOR SUPPORTING IMMUNE HEALTH | February 2022 | August 2024 | Allow | 30 | 2 | 1 | No | No |
| 17635266 | HYDRATING PATCH | February 2022 | September 2025 | Allow | 43 | 2 | 1 | No | No |
| 17634187 | A Method for Treatment of Crops | February 2022 | August 2025 | Allow | 42 | 2 | 0 | No | No |
| 17627524 | SKIN CARE COMPOSITONS COMPRISING SYNERGISTIC BLEND OF SACRED LOTUS AND TEA PLANT OR SACRED LOTUS AND GERMAN CHAMOMILE AND COSMETIC APPLICATIONS THEREOF | January 2022 | March 2025 | Allow | 38 | 2 | 1 | No | No |
| 17626859 | WATER-IN-OIL EMULSION COMPOSITION FOR ENHANCED DELIVERY OF WATER SOLUBLE SKIN BENEFIT AGENTS | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17625752 | COMPOSITIONS, MEANS AND METHODS FOR A NOVEL INSECT REPELLENT | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17569958 | CHINESE HERBAL MEDICINE COMPOSITION FOR RELIEVING HEARING LOSS AND PREPARATION METHOD AND USE THEREOF | January 2022 | October 2025 | Abandon | 46 | 6 | 1 | No | No |
| 17623922 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | December 2021 | April 2025 | Allow | 39 | 1 | 1 | No | No |
| 17622525 | MUSCLE FATIGUE RECOVERY PROMOTING AGENT AND METHOD FOR PRODUCING MUSCLE FATIGUE RECOVERY-PROMOTING LIQUID | December 2021 | November 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17622607 | COMPOSITION COMPRISING INGREDIENTS FOR DIC-GEL AND POLYOL | December 2021 | January 2026 | Allow | 49 | 4 | 0 | No | No |
| 17555258 | COMPOSITIONS AND METHODS FOR INHIBITING YEAST INFECTIONS | December 2021 | October 2024 | Abandon | 34 | 3 | 1 | No | No |
| 17619702 | STABLE AQUEOUS SUSPENSION FORMULATIONS | December 2021 | August 2025 | Allow | 44 | 1 | 1 | No | No |
| 17596627 | DEGRADABLE REGENERATIVE MEDICAL MATERIAL FOR PROMOTING TISSUE IN-SITU REGENERATION AND PREPARATION METHOD THEREFOR | December 2021 | May 2025 | Allow | 41 | 1 | 1 | No | No |
| 17619474 | COMPOSITION COMPRISING METFORMIN HCI, VITAMIN B12 AND AT LEAST ONE FLOW ADDITIVE | December 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17616569 | METHODS AND COMPOSITIONS FOR MICROFLILLNG THE SKIN WITH HYALURONIC ACID USING MICROCHANNEL TECHNOLOGY | December 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17613012 | COMPOSITIONS AND METHODS TO TREAT CANCER | November 2021 | September 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17612258 | FREEZE-RESISTANT DISINFECTANT COMPOSITION AND PREPARATION METHOD THEREFOR | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17494598 | HERBAL FORMULATION AND METHOD OF ADMINISTERING THE SAME | October 2021 | November 2024 | Abandon | 37 | 4 | 0 | No | No |
| 17435568 | Composition for Increasing Occupancy of Faecalibacterium in Intestinal Flora | September 2021 | March 2025 | Abandon | 43 | 2 | 0 | Yes | No |
| 17408646 | DELIVERY PARTICLE | August 2021 | May 2024 | Allow | 33 | 3 | 0 | No | No |
| 17432509 | DENTAL DEVICE FOR RIDGE PRESERVATION AND PROMOTION OF JAW BONE REGENERATION IN AN EXTRACTION SITE | August 2021 | October 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17339618 | AMANTADINE COMPOSITIONS, PREPARATIONS THEREOF, AND METHODS OF USE | June 2021 | June 2024 | Allow | 37 | 2 | 1 | No | No |
| 17288392 | TOPICAL COMPOSITION COMPRISING AN INORGANIC UV-FILTER | April 2021 | December 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17238882 | HOLLOW CORE GRANULES, PRODUCTS INCORPORATING THE GRANULES, AND METHODS OF PREPARING THE GRANULES | April 2021 | January 2026 | Allow | 57 | 5 | 1 | Yes | Yes |
| 16077722 | DRUG-LOADED TISSUE ADHESIVE FILM AND PREPARATION METHOD THEREFOR | April 2021 | December 2024 | Abandon | 60 | 2 | 0 | No | No |
| 17285711 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | April 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17284989 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | April 2021 | August 2025 | Allow | 52 | 4 | 1 | Yes | No |
| 16760898 | DELIVERY SYSTEMS FOR ADMINISTRATION OF CATIONIC BIOLOGICAL ACTIVES | April 2021 | October 2025 | Allow | 60 | 2 | 1 | No | No |
| 17274306 | Fast-Acting Soft Gelatin Capsules Containing A Mixture Of Pain Reliever/Fever Reducer, Diuretic And Antihistamine | March 2021 | January 2026 | Abandon | 58 | 4 | 1 | Yes | No |
| 17272756 | AN IRON CONTAINING COMPOSITION AND USE THEREOF | March 2021 | September 2024 | Allow | 43 | 2 | 1 | No | No |
| 17271150 | THERAPEUTIC COMBINATIONS OF BOSWELLIA EXTRACT AND CANNABINOIDS | February 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17269497 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER CELLS BY INDUCTION OF CYTOTOXIC OXIDATIVE STRESS | February 2021 | January 2025 | Allow | 47 | 2 | 1 | No | No |
| 17268751 | ANTIMICROBIAL COMPOSITION | February 2021 | October 2025 | Abandon | 56 | 4 | 1 | No | No |
| 17250559 | Pet Food Compositions | February 2021 | March 2025 | Allow | 49 | 5 | 1 | Yes | No |
| 17263600 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | January 2021 | July 2024 | Allow | 42 | 2 | 1 | No | No |
| 17153496 | COMPOSITIONS, USES AND METHODS FOR TREATMENT AND/OR PREVENTION OF ELEVATED CHOLESTEROL, HYPERCHOLESTEROLEMIA, AND CARDIOVASCULAR DISEASE | January 2021 | February 2026 | Abandon | 60 | 2 | 1 | No | Yes |
| 17059233 | SINGLE CELL ENCAPSULATION VIA PICKERING EMULSION FOR BIO-PESTICIDES APPLICATION | November 2020 | November 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 17059221 | METHOD FOR ENHANCING EMBRYO IMPLANTATION | November 2020 | September 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 17044377 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | October 2020 | September 2024 | Allow | 48 | 3 | 1 | No | No |
| 17039426 | Composition for the Modulation of Circadian Rhythmicity and Sleep Quality | September 2020 | December 2024 | Abandon | 50 | 4 | 1 | No | No |
| 16873552 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | April 2020 | March 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 16647976 | Conductive Graphene/Carbon Nanofiber Composite Scaffold, its use for neural tissue engineering and a method of preparation thereof | March 2020 | December 2024 | Allow | 57 | 3 | 1 | No | No |
| 16631184 | NEW KIND OF WOUND DRESSING FOR HAEMOSTASIS | January 2020 | September 2024 | Allow | 57 | 4 | 1 | Yes | No |
| 16731870 | HAIR COLORING COMPOSITIONS AND METHODS OF USE | December 2019 | November 2024 | Allow | 58 | 2 | 0 | No | Yes |
| 16448927 | SOLID PHARMACEUTICAL FORMULATIONS OF ASIMADOLINE | June 2019 | October 2024 | Allow | 60 | 7 | 0 | Yes | Yes |
| 16162060 | Compositions and Methods to Enhance Ultrasound-Mediated Delivery of Pharmaceutical Agents | October 2018 | May 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 15682764 | CHEMICALLY STABLE COMPOSITIONS OF A PHARMACEUTICAL ACTIVE AGENT IN A MULTI-CHAMBERED DELIVERY SYSTEM FOR MUCOSAL DELIVERY | August 2017 | July 2019 | Allow | 23 | 2 | 1 | Yes | No |
| 15096957 | Method of Treating Multiple Sclerosis | April 2016 | September 2018 | Allow | 29 | 3 | 1 | Yes | No |
| 14899039 | CATIONIC GROUP-CONTAINING CELLULOSE ETHER | December 2015 | September 2017 | Allow | 21 | 1 | 1 | Yes | No |
| 14934135 | METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS WITH RAPAMYCIN IN A STABLE, SUPER-SATURATED STATE | November 2015 | November 2024 | Abandon | 60 | 9 | 1 | Yes | Yes |
| 14877916 | METHOD OF TREATING DIABETIC WOUNDS USING BIOSYNTHESIZED NANOPARTICLES | October 2015 | June 2016 | Allow | 8 | 3 | 1 | Yes | No |
| 14774255 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | September 2015 | June 2018 | Allow | 44 | 3 | 1 | Yes | No |
| 14796928 | BIOLOGICAL INFORMATION ACQUISITION METHOD AND INSTRUMENT, AND PHYSIOLOGICALLY-ACTIVE SUBSTANCE MEASUREMENT METHOD AND INSTRUMENT | July 2015 | April 2016 | Allow | 10 | 1 | 0 | No | No |
| 14605265 | BIOACTIVE LOAD-BEARING COMPOSITES | January 2015 | February 2016 | Allow | 13 | 1 | 0 | No | No |
| 14537764 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | November 2014 | June 2016 | Allow | 20 | 1 | 1 | Yes | No |
| 14382985 | SILICON DIOXIDE IN SHAVING PRODUCTS | September 2014 | September 2015 | Allow | 13 | 0 | 0 | Yes | No |
| 14458625 | METHOD OF TREATING MULTIPLE SCLEROSIS | August 2014 | December 2015 | Allow | 16 | 0 | 1 | Yes | No |
| 14376595 | COMPOSITIONS FOR INCREASING HAIR GROWTH | August 2014 | January 2016 | Allow | 17 | 1 | 0 | Yes | No |
| 14337776 | VASCULAR CLOSURE DEVICE | July 2014 | November 2014 | Allow | 3 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PARK, HAEJIN S.
With a 60.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner PARK, HAEJIN S works in Art Unit 1614 and has examined 98 patent applications in our dataset. With an allowance rate of 83.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner PARK, HAEJIN S's allowance rate of 83.7% places them in the 58% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by PARK, HAEJIN S receive 2.35 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PARK, HAEJIN S is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +29.0% benefit to allowance rate for applications examined by PARK, HAEJIN S. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.5% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 36.1% of cases where such amendments are filed. This entry rate is in the 54% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 61.5% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 37.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 62.5% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.0% of allowed cases (in the 75% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.